Compare Adaptive Biotechnologies Corp (ADPT) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs SoundHound AI Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while SoundHound AI Inc trades at $6.67 (market cap $2.88B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | SOUN | |
|---|---|---|
Market Cap | $3.33B | $2.88B |
Sector | Health | Technology |
52-Week High | $22.37 | $21.40 |
52-Week Low | $10.24 | $5.90 |
Enterprise Value | $3.19B | $2.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SoundHound AI (SOUN) trades at $6.96, up 6.26% on the day, with a bearish technical signal despite recent positive earnings beats. The company shows strong revenue growth in auto and IoT AI segments, up 88% year-over-year in Q1 2026, but faces profitability challenges with a net income margin of -91.84% and negative cash flow from operations. Analyst sentiment remains bullish with a $13.00 consensus price target, though the stock is down 37% year-to-date amid concerns over the LivePerson acquisition and high valuation multiples.
The outlook hinges on SOUN's ability to achieve profitability through scaling and cost synergies from acquisitions. Investment opportunities include market expansion in telecom and energy sectors, while risks involve persistent cash burn, competitive pressures, and execution risks in integrating LivePerson. The stock's high short interest could lead to volatility, but analyst optimism suggests potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
